The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cognitive decline, and continuous treatment may help maintain early disease stages longer. Safety data aligned with FDA guidelines, with manageable side effects. This real-world evidence supports LEQEMBI's long-term benefits beyond clinical trials.
Biogen has chosen Veeva Vault CRM as its global commercial platform to enhance the delivery of medicines to patients. This platform uses AI-driven tools to support a flexible commercial strategy, helping Biogen bring complex treatments to market more...
Eisai and Biogen have launched LEQEMBI IQLIK, the first weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. This treatment offers a convenient alternative to intravenous infusions, allowing patients to initiate and ...
